All In Biotech

Drug Trial Radar · NCT04217733

Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

A Comparative Study to Assess Safety and Effectiveness of Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 1, 2019

Primary completion

Dec 1, 2030

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Tanta UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome

Conditions

  • IBS - Irritable Bowel Syndrome

Interventions

  • pentoxyifyllineDrug

    Pentoxyifylline two times daily for 3 months

  • MebeverineDrug

    Mebeverine 3 times for 3 months

  • ethosuximideDrug

    ethosuximide 3 times for 3 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with improved Visual analog scales (VAS) for assessment of pain in IBSTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sherief Abd-Elsalam

    Tanta, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.